AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05364385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Infants in the control group (S/P group) receive placebo (Normal saline 1mL)
Description: Infants in the control group (S/P group) will receive surfactant 2.5 mls/kg and placebo (Normal saline 1mL)
Study NCT04447287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8062
Description: Oral
Study NCT04447287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ASP8062
Description: Oral
Study NCT04447287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone
Description: Sublingual
Study NCT04447287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: buprenorphine/naloxone
Description: Sublingual
Study NCT04197622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: 12,5 mg of hydrochlorothiazide (1/2 tablet of 25 mg) administered orally in a single dose.
Study NCT03350698 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil-9
Description: 3 vaccine series
Study NCT01732120 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Off-clamp partial nephrectomy
Study NCT02933294 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Triportal pulmonary resection surgery
Description: Uniportal video-assisted thoracoscopic surgery
Study NCT02933294 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uniportal pulmonary resection surgery
Description: Triportal video-assisted thoracoscopic surgery
Study NCT00023920 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT02485002 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RIRS with ureteral access sheath
Description: Ureteral access sheath will be used during RIRS.
Study NCT02485002 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIRS without ureteral access sheath
Description: Ureteral access sheath will not be used during RIRS.
Study NCT03675334 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root coverage with collagen matrix graft
Description: at one side, the root coverage have been done with a extended flap technique and collagen matrix graft. At the other side, the same technique was performed with connective graft.
Study NCT03675334 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Root coverage with subepithelial connective tissue graft
Description: at one side, the root coverage have been done with a extended flap technique and collagen matrix graft. At the other side, the same technique was performed with connective graft.
Study NCT03675334 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Basic periodontal treatment
Description: profilaxis, coronary polishing and scaling and root planning
Study NCT03675334 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basic periodontal treatment
Description: profilaxis, coronary polishing and scaling and root planning
Study NCT01397708 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INXN-2001
Description: * approximately 1.0 x 1012 viral particles (vp) per injection~* one intratumoral injection of INXN-2001 per study cycle~* maximum of 6 study cycles
Study NCT01397708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INXN-1001
Description: * 4 dose cohorts (5mg/day, 20mg/day, 100mg/day, and 160mg/day)~* 7 oral daily doses of INXN-1001 per study cycle~* maximum of 6 study cycles~* 1 Expansion cohort at a single dose level at or below MTD (160mg/day)
Study NCT02197026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylan G-F 20
Study NCT02197026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard drug treatment at the discretion of the investigator
Study NCT02197026 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Study NCT02197026 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hydrotherapy
Study NCT00698789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB019602
Description: 7.5 mg in PM QoD with placebo administration in AM as well as PM on non-active dose days
Study NCT00698789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administration in AM or PM depending on treatment arm dosing regimen.
Study NCT00698789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administration in AM or PM depending on treatment arm dosing regimen.
Study NCT00698789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Stable dose metformin monotherapy
Study NCT00698789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Stable dose metformin monotherapy
Study NCT03243721 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neurocognitive testing
Description: A series of tests to assess memory, verbal skills, and visuospatial skills.
Study NCT05795907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR443820
Description: Capsule / Oral
Study NCT01343290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Type = 1, unit = mg, number = 300, form = tablet, route = oral use. Single tablet taken with or without a meal during 2 treatment periods
Study NCT04653818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velpatasvir/Sofosbuvir
Description: sofosbuvir / velpatasvir will be given for 12 weeks aiming to eradicate HCV. Ribavirin will be added for Child-Pugh B patients or treatment will be extended for 24 weeks for those who are Ribavirin intolerant.
Study NCT02803801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Build Your Parenting Toolkit Program
Description: Ten session program, with a mix of parents-only lectures and parent and child Cooking Clubs.
Study NCT04944446 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment
Description: Myofascial release of various muscle groups Treatment of mobilization of the shoulder joint
Study NCT04944446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Myofascial release of various muscle groups Treatment of mobilization of the shoulder joint
Study NCT03547791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethason Sodium Phosphate
Description: The antecorticosteroid that will be administered to Group 1 is betamethasone, produced by Dawon Parm(Korea). It contains betamethason sodium phosphate 5.2mg(Betamethasone 4.0mg) in 1 ample(1mL). Each drug is carried in a syringe by pharmacist who does not participate in study after the patient was enrolled in the study and administered to the patient twice 24hours apart.
Study NCT03547791 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Intramuscular injection of normal saline 3ml twice 24hours apart
Study NCT00394407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sliding scale regular insulin
Description: SSRI acqhs
Study NCT05795907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Capsule / Oral
Study NCT00394407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glargine basal insulin and glulisine prandial insulin
Description: glargine insulin once a day and glulisine insulin three times a day as long as patient eating
Study NCT04737681 — intervention group
Intervention type: OTHER
Intervention: body composition
Description: This is an observational study to determine immune response and skin barrier restoration in individuals with and without obesity.
Study NCT02059044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ISTOP-ADE
Description: Interactive Voice Response System + Pharmacist
Study NCT02555449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [¹⁴C]-LY3202626
Description: Administered as solution by mouth
Study NCT03712930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: 60 mg orally twice daily (BID)
Study NCT03479034 — intervention group
Intervention type: OTHER
Intervention: ScalaMed ePrescription application
Description: Mobile phone application (Android and Apple) for storing electronic prescriptions
Study NCT02986906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% dextrose
Description: Ultrasound-guided 5cc 5% dextrose injection between medial epicondyle and ulnar nerve
Study NCT01701882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir/emtricitabine/rilpivirine
Study NCT05201131 — intervention group
Intervention type: PROCEDURE
Intervention: Rezum
Description: Rezum
Study NCT00158678 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IMRT 75 Gy
Description: 50 Gy in PTV1 and 25 Gy in 10 fractions in PTV2
Study NCT01666418 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pazopanib/Paclitaxel
Study NCT00158678 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional radiotherapy 70 Gy
Description: 50 Gy in PTV1 and 20 Gy in PTV2
Study NCT02986906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2cc 0.9% normal saline+3cc Triamcinolone (30mg)
Description: Ultrasound-guided 2cc 0.9% normal saline+3cc Triamcinolone (30mg) injection between medial epicondyle and ulnar nerve
Study NCT00158678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: concomitant cisplatin
Description: 100 mg/m2 D1, D22, D43
Study NCT00158678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concomitant cisplatin
Description: 100 mg/m2 D1, D22, D43
Study NCT02986906 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: The ultrasound was used for injection guidance
Study NCT00578799 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Kyo-Dophilus
Description: 5x109 bacteria/capsule, twice a day, 1 in the morning, 1 in the evening
Study NCT00578799 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules (potato starch
Study NCT03752606 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TACHOSIL GROUP
Study NCT02915952 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zip Surgical Skin Closure Device
Description: The Zip Surgical Skin Closure Device will be used for surgical wound closure in C-Section Surgery
Study NCT02915952 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Sutures
Description: Conventional Sutures will be used for surgical wound closure in C-Section Surgery
Study NCT00945074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Acupuncture/Moxibustion (fixed protocol)
Description: Acupuncture/Moxibustion
Study NCT00945074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized Acupuncture/Moxibustion
Description: Individualized Tailored Acupuncture/Moxibustion Protocol based on TCM Diagnosis
Study NCT00945074 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham/Placebo Acupuncture/Moxibustion
Description: Sham/Placebo Acupuncture/Moxibustion Protocol: Not-Active
Study NCT02569619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity Intervention
Study NCT02569619 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Diet Intervention
Study NCT02299765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: patients in arm A will be given gefitinib as target therapy
Study NCT02299765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: patients in arm A will be given gefitinib as target therapy
Study NCT02299765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: patients in arm A will be given gemcitabine chemotherapy
Study NCT02299765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: patients in arm A will be given carboplatin chemotherapy
Study NCT03230344 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open flap debridement
Description: open flap debridement simultaneously with root canal treatment
Study NCT03230344 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open flap debridement
Description: open flap debridement and delayed root canal treatment
Study NCT03518814 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: FACT-M (Functional Assessment of Cancer Therapy - Melanoma) questionnaire, MOS SF (medical outcome study short form) -36 questionnaire
Study NCT04496440 — intervention group
Intervention type: OTHER
Intervention: Contracture Correction Therapy
Description: Non-drug and non-surgical treatment of contracted knee capsules
Study NCT00358995 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Participants will be randomly assigned to either immediate treatment or delayed treatment (three month delay). Participants will then be again be randomly assigned to either Cognitive Behavior Therapy (CBT) or Stress Management Therapy (SMT). The delayed participants (wait list control) will be randomly assigned to either of the two active treatment groups in three months time. Both active treatment conditions involve one hours, individual treatment sessions for 12 consecutive weeks by one of the treating psychologists. All participants will also be asked to complete a package of psychometric questionnaires before treatment.
Study NCT00358995 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management Therapy (SMT)
Description: Participants will be randomly assigned to either immediate treatment or delayed treatment (three month delay). Participants will then be again be randomly assigned to either Cognitive Behavior Therapy (CBT) or Stress Management Therapy (SMT). The delayed participants (wait list control) will be randomly assigned to either of the two active treatment groups in three months time. Both active treatment conditions involve one hours, individual treatment sessions for 12 consecutive weeks by one of the treating psychologists. All participants will also be asked to complete a package of psychometric questionnaires before treatment.
Study NCT02986906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: The ultrasound was used for injection guidance
Study NCT00462826 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ziv-aflibercept
Study NCT02976532 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electromagnetic tracking unit in femoral derotation surgery
Description: Use of the electromagnetic tracking system during the surgical procedure in addition to the normal measurement with goniometer, the different devices listed are combined to form the EMT system unit
Study NCT05900193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TAS1R2/3 agonist or antagoinst admixture to oral glucose tolerance test
Description: Participants drank a glucose beverage for an oral glucose tolerance test along or with admixture with the TAS1R2/3 agonist sucralose or the TAS1R2/3 antagonist lactisole.
Study NCT04264767 — intervention group
Intervention type: PROCEDURE
Intervention: Blood collection
Description: Peripheral blood collection via routine venipuncture
Study NCT01665521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HEART Pathway
Description: During ED evaluation, patients are randomized to HEART Pathway or usual care arms.
Study NCT03675438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sub-epitheilal TCA Inlay
Description: A TCA lenticule is placed at the sub-epithelial interface with the anterior surface of Bowmans layer
Study NCT03013205 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraarticular triamcinolone injection
Description: triamcinolone 10mg/mL
Study NCT04983784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: walking
Description: walking for 12 weeks at home
Study NCT02743143 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Study NCT02743143 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up care as usual
Study NCT03013205 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraarticular triamcinolone injection
Description: triamcinolone 10mg/mL
Study NCT03013205 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraarticular Xylocaine injection
Description: Xylocaine 1% 4ml
Study NCT03013205 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraarticular Xylocaine injection
Description: Xylocaine 1% 4ml
Study NCT03013205 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coracohumeral ligament triamcinolone injection
Description: triamcinolone 10mg/mL
Study NCT03013205 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Study NCT01176019 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Information about Prenatal Screening and Diagnosis
Description: 15-20 minute interactive video about prenatal screening and diagnosis given on day of recruitment.
Study NCT02458092 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum Malaria Protein 010 (FMP010)
Description: Vaccine antigen is a recombinant protein based on merozoite surface protein-1 (MSP-1) of FVO strain of Plasmodium falciparum, and adjuvant AS01B is a proprietary adjuvant of GSK
Study NCT02458092 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabipur
Description: Rabipur is a licensed rabies vaccine.
Study NCT04983784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine care
Description: Routine care
Study NCT03013205 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Study NCT04469374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jumping exercise
Description: Participants will be required to perform 10 maximal vertical jumps, with a 10-s rest interval between each jump, using an arm swing in countermovement style on three days per week. The jumps will be performed without shoes on a hard surface. The jumps will be preceded by a warm-up lasting approximately 3 min and consisting of mobilisation exercises for the legs and lower back. Jumping will be progressed over time and in accordance with individual needs.
Study NCT04469374 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Balance exercise (sham control)
Description: Participants will be required to perform balance exercises. Participants will be required to balance on one leg for up to 60 seconds (2 x 60 s is equivalent in duration to the 10 jumps). This exercise will be progressed.
Study NCT04982159 — intervention group
Intervention type: OTHER
Intervention: There is no intervention. This is an observational study.
Description: There is no intervention. This is an observational study.
Study NCT04464668 — intervention group
Intervention type: BEHAVIORAL
Intervention: Provider Tools
Description: Providers will be trained to use Electronic Medical Record (EMR) tools and prompts, and an organization wide cancer control champion will be trained to motivate providers and navigate patients.
Study NCT04461132 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Lymphatic drainage (MLD)
Description: MLD vith vodder technique was applied to leg
Study NCT04461132 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Skin Care
Description: Wound was cleaned with salin and covered by dressing without including active products
Study NCT04461132 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Skin Care
Description: Wound was cleaned with salin and covered by dressing without including active products
Study NCT04461132 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: breathing and foot pump exercise was prescribed
Study NCT04461132 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: breathing and foot pump exercise was prescribed
Study NCT03357289 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mix vaccine
Description: Each treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle
Study NCT03849495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-370
Description: Test drug
Study NCT04461132 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Shame Manual Lymphatic drainage
Description: manual lymphatic drainage was applied with light touch instead of real mld techniques
Study NCT03996551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ExeRTiOn online resource
Description: This is a 12-week online resource, specifically designed for new kidney transplant recipients. It includes dietary advice, physical activity advice, and recognized behavior change techniques. The participant will be monitored by a specialist physiotherapist and will receive messages of encouragement a 6 weeks and 12 weeks.
Study NCT02938520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir (CAB) tablet
Description: It is a white oval shaped film coated 30 mg tablets for oral administration. CAB Tablet is composed of cabotegravir sodium, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-coat.